PE20081360A1 - Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal - Google Patents

Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal

Info

Publication number
PE20081360A1
PE20081360A1 PE2007001139A PE2007001139A PE20081360A1 PE 20081360 A1 PE20081360 A1 PE 20081360A1 PE 2007001139 A PE2007001139 A PE 2007001139A PE 2007001139 A PE2007001139 A PE 2007001139A PE 20081360 A1 PE20081360 A1 PE 20081360A1
Authority
PE
Peru
Prior art keywords
lipoxin
prevention
treatment
analog compounds
intestinal fibrosis
Prior art date
Application number
PE2007001139A
Other languages
English (en)
Inventor
John Parkinson
Stefano Fiorucci
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20081360A1 publication Critical patent/PE20081360A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS ANALOGOS DE LIPOXINA A4 DE FORMULA (I) O (II), EN DONDE R1, R2 Y R3 SON INDEPENDIENTEMENTE HALO, -OR6, -SR6, S(O)tR7 (t ES 1 O 2) O -N(R7)R8; O R1 Y R2 JUNTO A LOS ATOMOS A LOS CUALES ESTAN UNIDOS FORMAN UN GRUPO DE FORMULA a), b), ENTRE OTROS; R4 ES -R9-R12, -R9-O-R10-R11, -R9-S(O)t-R10-R11, ENTRE OTROS, DONDE t ES DE 0 A 2; R5 ES ARILO O ARALQUILO OPCIONALMENTE SUSTITUIDOS CON ALQUILO, ALCOXILO, HALO, HALOALQUILO Y HALOALCOXILO; SIENDO PREFERIDO ACIDO 2-((2S,3R,4E,6E,10E,12S)-13-(4-FLUOROFENOXI)-2,3,12-TRIHIDROXITRIDECA-4,6,10-TRIEN-8-INILOXI)ACETICO, COMO ESTEREOISOMERO, MEZCLA RACEMICA O COMO CLATRATO DE CICLODEXTRINA, INDICADO PARA EL TRATAMIENTO Y/O PREVENCION DE LA FIBROSIS INTESTINAL
PE2007001139A 2006-08-23 2007-08-22 Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal PE20081360A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83975506P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
PE20081360A1 true PE20081360A1 (es) 2008-11-29

Family

ID=39107156

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001139A PE20081360A1 (es) 2006-08-23 2007-08-22 Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal

Country Status (18)

Country Link
US (1) US20080119439A1 (es)
EP (1) EP2056816A2 (es)
JP (1) JP2010501506A (es)
KR (1) KR20090042982A (es)
CN (1) CN101528219A (es)
AR (1) AR062478A1 (es)
AU (1) AU2007287770A1 (es)
BR (1) BRPI0716576A2 (es)
CA (1) CA2660741A1 (es)
CL (1) CL2007002442A1 (es)
IL (1) IL196983A0 (es)
MX (1) MX2009001994A (es)
PE (1) PE20081360A1 (es)
RU (1) RU2009110244A (es)
TW (1) TW200816991A (es)
UY (1) UY30557A1 (es)
WO (1) WO2008022807A2 (es)
ZA (1) ZA200902005B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140984A1 (en) * 2008-05-22 2009-11-26 Bayer Schering Pharma Aktiengesellschaft Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid
CA2856016C (en) 2011-11-18 2020-09-22 Tokiyoshi AYABE Agent for treating fibrosis of the intestine
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
WO2020086704A1 (en) * 2018-10-23 2020-04-30 The Brigham And Women's Hospital, Inc. Lipoxin a4 analogs and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs

Also Published As

Publication number Publication date
BRPI0716576A2 (pt) 2014-02-18
WO2008022807A2 (en) 2008-02-28
CL2007002442A1 (es) 2008-03-14
JP2010501506A (ja) 2010-01-21
CN101528219A (zh) 2009-09-09
UY30557A1 (es) 2008-03-31
MX2009001994A (es) 2009-03-06
KR20090042982A (ko) 2009-05-04
AR062478A1 (es) 2008-11-12
IL196983A0 (en) 2009-11-18
US20080119439A1 (en) 2008-05-22
EP2056816A2 (en) 2009-05-13
AU2007287770A1 (en) 2008-02-28
ZA200902005B (en) 2010-05-26
WO2008022807A3 (en) 2008-05-29
TW200816991A (en) 2008-04-16
CA2660741A1 (en) 2008-02-28
RU2009110244A (ru) 2010-09-27

Similar Documents

Publication Publication Date Title
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
EA201101587A1 (ru) 4-циано-3-бензоиламино-n-фенилбензамиды для использования в борьбе с вредителями
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
ECSP10010405A (es) Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
CY1115226T1 (el) Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
ECSP066784A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
MX2011013448A (es) Compuestos insecticidas.
EA201101588A1 (ru) Инсектицидные соединения
UY30533A1 (es) Acetamidas n-{1-[4(1-ciano-1-metil)fenil]etil}sustituidas derivadas del acido 2-(1h-bencimidazol-1il) acético
IN2014MN01521A (es)
MX2011007952A (es) Tricianoboratos novedosos.
HK1126756A1 (en) Process for preparation of hiv protease inhibitors
PE20110420A1 (es) Nuevos derivados de 2-amidotiadiazol
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
PE20120689A1 (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
EA201171167A1 (ru) Карбинольное соединение, содержащее гетероциклический линкер
PE20081360A1 (es) Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal

Legal Events

Date Code Title Description
FD Application declared void or lapsed